High-dose chemotherapy in breast cancer: the end of the beginning?
Antman
K H
KH
Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004644:Emotions; D005260:Female; D005602:France; D006291:Health Policy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009426:Netherlands; D018579:Patient Selection; D010820:Physicians / Q000523:psychology; D011057:Politics; D011639:Public Opinion; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016879:Salvage Therapy; D012537:Scandinavian and Nordic Countries; D013019:South Africa; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States